NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Wednesday, April 30, 2025 6:52

Release 3.292
DIVENCE IBR MARKER LIVE lyophilisate and solvent for emulsion for injection (NI Only)
 
Species: Cattle
Therapeutic indication: Immunological veterinary medical products: For cattle
Active ingredient: Vaccine Antigens
Product:DIVENCE IBR MARKER LIVE lyophilisate and solvent for emulsion for injection
Product index: Divence IBR Marker Live
Cattle - milk: Zero Days
Cattle - meat: Zero Days
Incorporating:
Presentation
Presentation
Lyophilisate and solvent for emulsion for injection
Uses
Indications for use
Active immunisation of cattle from 10 weeks of age to reduce virus shedding, hyperthermia and clinical signs of IBR (infectious bovine rhinotracheitis).
Onset of immunity: 3 weeks after completion of the basic vaccination scheme.
Duration of immunity: 6 months after completion of the basic vaccination scheme.
1 year after completion of the re-vaccination scheme.
Dosage and administration
Administration routes and dosage
Intramuscular use.
For use in cattle from 10 weeks of age onwards.
Basic vaccination scheme: administer two doses (2 ml each) with an interval of 3 weeks.
Re-vaccination scheme: one dose of 2 ml should be administered at an interval not longer than 6 months after completion of the basic vaccination scheme.
Subsequent re-vaccination scheme: one dose of 2 ml should be administered at an interval not longer than 12 months.
The vaccine may be used for subsequent re-vaccinations after vaccination with DIVENCE PENTA vaccine, if there is no further need for protection against BRSV, PI-3 or BVDV.
Method of administration:
Avoid contamination during reconstitution and use. Use only sterile needles and syringes for administration.
Reconstitute the lyophilisate with the corresponding volume of solvent:
Number of doses per vial of lyophilisate
Volume of solvent to be used
5 doses
10 ml
20 doses
40 ml
40 doses
80 ml
50 doses
100 ml
1. Peel the top of the aluminium cap on the vial containing the solvent and withdraw 10 ml of volume.
2. Inject the solvent into the vial containing the lyophilisate.
3. Shake until the lyophilisate is in emulsion. The 5-doses vial is now ready to use.
4. For the 20, 40 and 50 doses vials, once the lyophilisate is in emulsion with the 10 ml of solvent, withdraw all the emulsion obtained from the vaccine vial and inject it into the vial containing the remaining solvent.
5. Shake until the lyophilisate is in emulsion.
The reconstituted vaccine is a white-to-yellow emulsion.
Contra-indications, warnings, etc
Contraindications
None.
Special warnings
Vaccinate healthy animals only.
Special precautions for use
Special precautions for safe use in the target species:
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected, and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.
To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Special precautions for the protection of the environment:
Not applicable.
Adverse events
Cattle:
Very common (≥1 animal / 10 animals treated): Injection site inflammation1, elevated temperature2
Uncommon (1 to 10 animals / 1,000 animals treated): Anaphylactic-type reaction3
1 A slight to moderate transient injection site inflammation (up to 14 cm of diameter) may be observed, which rapidly decreases in diameter within 2 days and subsides within 2 weeks without treatment.
2 An elevated temperature (mean increase 1.7 ºC, in individual animals up to 2.4 ºC) may occur after vaccination. This increase subsides spontaneously within 3 days.
3 In cases of anaphylactic-type reactions, an appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
Can be used during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
No adverse events other than those described above were observed .
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State’s competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Official control authority batch release may be required for this product according to national requirements.
Withdrawal periods
Zero days.
Pharmaceutical precautions
PHARMACEUTICAL PARTICULARS
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
Active substances:
Live gE- tk- double gene-deleted bovine herpesvirus type 1 (BoHV-1), strain CEDDEL 106.3 - 107.6 CCID50*
gE- : deleted glycoprotein E ; tk- : deleted thymidine kinase
* Cell Culture Infectious Dose 50 %
Adjuvant:
Montanide IMS 1.010 g
Excipients: Qualitative composition of excipients and other constituents
Lyophilisate: Dipotassium phosphate, Gelatin, Glycine, Potassium dihydrogen phosphate, Sorbitol, Sucrose
Solvent: Disodium phosphate dodecahydrate, Potassium chloride, Potassium dihydrogen phosphate, Sodium chloride, Water for injections
Lyophilisate: white-to-yellow colour Solvent: white translucent emulsion.
Major incompatibilities
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 18 months. Shelf life of the solvent as packaged for sale: 3 years.
Shelf life after reconstitution according to directions: 2 hours.
Special precautions for storage
Store and transport refrigerated (2 °C - 8 °C). Do not freeze. Protect from light.
Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.
Legal category
Legal category: POM-V
Packaging quantities
Nature and composition of immediate packaging
Lyophilisate: 10 ml type I glass vials containing 5 doses, 20 doses, 40 doses or 50 doses, closed with bromobutyl rubber stoppers and sealed with aluminium caps.
Solvent: Polyethylene (PET) vials of 10 ml, 50 ml, 100 ml, closed with bromobutyl rubber stoppers and sealed with aluminium caps.
Pack sizes:
Cardboard box containing 1 vial of 5 doses of lyophilisate and 1 vial containing 10 ml of solvent. Cardboard box containing 1 vial of 20 doses of lyophilisate and 1 vial containing 40 ml of solvent. Cardboard box containing 1 vial of 40 doses of lyophilisate and 1 vial containing 80 ml of solvent. Cardboard box containing 1 vial of 50 doses of lyophilisate and 1 vial containing 100 ml of solvent.
Not all pack sizes may be marketed.
Marketing Authorisation Holder (if different from distributor)
MA Holder: LABORATORIOS HIPRA, S.A.
Further information
IMMUNOLOGICAL INFORMATION
ATCvet code: QI02AD01
To stimulate active immunity against bovine herpesvirus type 1 (BoHV-1).
Vaccinated animals can be differentiated from field virus infected animals, due to the marker deletion (gE-) by means of commercial diagnostic kits.
Marketing Authorisation Number
MARKETING AUTHORISATION NUMBER(S): EU/2/24/318/001-004
Significant changes
GTIN
GTIN description:DIVENCE IBR ML Northern Ireland 5 ds
GTIN:GTIN12: 842771130986
GTIN description:DIVENCE IBR ML Northern Ireland 20 ds
GTIN:GTIN12: 842771130987